Edema
📧 Sign up to get email alerts when something new happens for Edema.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-14EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
EMA has authorized Qaialdo, a spironolactone product by Lipomed GmbH, for several conditions including edema, heart failure, liver cirrhosis…
-
EMA approval · 2026-03-24EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
Qaialdo is a spironolactone product by Lipomed GmbH that has been authorized in the EU. Indications include edema, heart failure, liver cirr…
-
FDA approval · 2026-01-08FDA Approved: FUROSEMIDE — Original Application (Micro Labs Limited)
FDA approved the original application for furosemide from Micro Labs Limited.
-
FDA approval · 2026-01-07FDA Approved: METOLAZONE — Supplemental Application (Method Pharmaceuticals, LLC)
The FDA approved a supplemental application for METOLAZONE submitted by Method Pharmaceuticals, LLC.
-
FDA approval · 2025-12-22FDA Approved: FUROSCIX — Supplemental Application (scPharmaceuticals Inc.)
The FDA approved a supplemental application for FUROSCIX (furosemide injection 80 mg/10 mL) from scPharmaceuticals Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-11-14FDA Approved: ALDACTONE — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approves a supplemental application for Aldactone (spironolactone) from Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2025-11-14FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application from Prasco Laboratories for Spironolactone and Hydrochlorothiazide, a combination diuretic. This re…
-
FDA approval · 2025-10-07FDA Approved: LASIX ONYU — Original Application (SQ Innovation, Inc.)
FDA approves LASIX ONYU for the same active ingredient furosemide under an Original Application by SQ Innovation, Inc. The product is now au…
-
FDA approval · 2025-09-08FDA Approved: FUROSEMIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for furosemide from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., updating/expandin…
-
FDA approval · 2025-08-06FDA Approved: FUROSEMIDE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for the generic diuretic furosemide from Meitheal Pharmaceuticals Inc. under ANDA 212803.
-
FDA approval · 2025-07-25FDA Approved: SPIRONOLACTONE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' generic spironolactone under an original application (ANDA 217761).
-
FDA approval · 2025-07-17FDA Approved: FUROSEMIDE — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's original ANDA for furosemide, a generic loop diuretic. The approval covers the generic product for i…
-
FDA approval · 2025-06-17FDA Approved: ACETAZOLAMIDE — Original Application (Sagent Pharmaceuticals)
FDA approved Sagent Pharmaceuticals' Original Application for Acetazolamide, including Acetazolamide and Acetazolamide Sodium formulations.
-
FDA approval · 2025-05-08FDA Approved: FUROSEMIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for furosemide by Eugia US LLC under an ANDA, confirming approval of the supplement.
-
FDA approval · 2025-04-03FDA Approved: BUMETANIDE — Original Application (First Nation Group, LLC)
FDA approves bumetanide under an Original Application filed by First Nation Group, LLC (ANDA219291).
-
FDA approval · 2025-03-17FDA Approved: HEMICLOR — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approves HemiclOR (chlorthalidone) through an Original Application by Ingenus Pharmaceuticals, LLC.
-
FDA approval · 2025-03-12FDA Approved: ACETAZOLAMIDE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved a supplemental application for acetazolamide submitted by Ajanta Pharma USA Inc.
-
FDA approval · 2025-01-28FDA Approved: INZIRQO — Original Application (ANI Pharmaceuticals, Inc.)
FDA approved INZIRQO, a brand-name hydrochlorothiazide, under ANI Pharmaceuticals' original application.
-
FDA approval · 2025-01-28FDA Approved: TRIAMTERENE AND HYDROCHLOROTHIAZIDE — Original Application (Macleods Pharmaceuticals Limited)
FDA approved a generic fixed-dose combination of triamterene and hydrochlorothiazide from Macleods Pharmaceuticals Limited under an origina…
-
FDA approval · 2025-01-23FDA Approved: SPIRONOLACTONE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved the original application for spironolactone (generic) from Rising Pharma Holdings, Inc., authorizing the marketing of a gen…
-
FDA approval · 2024-12-12FDA Approved: ACETAZOLAMIDE — Supplemental Application (Alembic Pharmaceuticals Inc.)
FDA approved a supplemental application for Acetazolamide from Alembic Pharmaceuticals Inc., indicating a supplemental approval for this gen…
-
FDA approval · 2024-10-01FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)
The FDA approved a supplemental application for furosemide from Phlow Corporation, authorizing an additional or revised approval for the diu…
-
FDA approval · 2024-09-19FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for hydrochlorothiazide from Teva Pharmaceuticals USA, Inc. The approval concerns regulatory changes…
-
FDA approval · 2024-09-19FDA Approved: BUMETANIDE — Original Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved bumetanide (Original Application) by Qilu Pharmaceutical as a generic diuretic for edema associated with congestive heart failu…
-
FDA approval · 2024-08-23FDA Approved: INDAPAMIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Indapamide submitted by Rising Pharma Holdings, Inc., under the ANDA.